The effects of discontinuation of vitamin K antagonists on the rate of elastin degradatio

• Conditions: Elastin-degradation; vitamin K deficiency; 10011082; 10024967; 10003216

• Registration Number: NL-OMON45726
• Lead Sponsor: Canisius Wilhelmina Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

VKA users who will discontinuate VKAs

Exclusion Criteria

life expectancy <6 months

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint is the change in the rate of elastin degradation<br /><br>quantified by the plasma desmosine assay. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are the change in vitamin K status quantified by measuring<br /><br>plasma levels of dephosphorylated uncarboxylated (dp-uc, i.e. inactive) Matrix<br /><br>Gla Protein (MGP), the relation between desmosine and dp-ucMGP and differences<br /><br>of desmosine and dp-ucMGP levels among subjects with different polymorphisms of<br /><br>the vitamin K 2,3-epoxide reductase complex 1 (VKORC1) gene. </p><br>